Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
EAST SETAUKET, N.Y., April 23 /PRNewswire-FirstCall/ -- Lixte Biotechnology Holdings (OTC Bulletin Board: LIXT) announced today that Dr. Jie Lu and Dr. Zhengping Zhuang of the Surgical Neurology Branch (SNB), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH) and its collaborator, Lixte Biotechnology Holdings. Inc., reported at the Annual Meeting of the American Association of Cancer Research that its lead compound LB-1, one of a patent-pending proprietary series of agents, has anti-cancer activity against human glioblastoma multiforme cells in a mouse model of cancer. Glioblastoma multiforme is the most common and aggressive brain tumor of adults.
The Dr. John S. Kovach, President and CEO of Lixte, said that the company and SNB, NINDS are continuing to develop LB-1 and analogs of the compound for the treatment of human brain cancers. Brain cancers pose a particular challenge to the development of effective drug treatments. The brain is protected by a physiological barrier that prevents the entry of many compounds from the blood into brain tissue. To be effective, drugs must be designed either to pass this barrier or be administered directly into the brain. "We are pursuing both strategies for the treatment of glioblastoma multiforme in a rat model in which the cancer is growing in the brain," said Dr. Kovach. "We want to be certain that we achieve drug delivery into the brain at concentrations that inhibit these tumors."
About Lixte Biotechnology Holdings, Inc.:
Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular abnormalities of common human cancers.
About the National Institute of Neurological Disorders and Stroke (NINDS), (NIH):
NINDS (www.ninds.nih.gov) is a component of the National Institutes of Health (NIH), and is the nation's primary supporter of biomedical research on the brain and nervous system.
The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the condensed consolidated financial statements and notes thereto included in Item 1 of the Quarterly Report on Form 10-QSB for the quarter ending September 30, 2007.
SOURCE Lixte Biotechnology Holdings